S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in

Akers Biosciences Stock Forecast, Price & News

-0.05 (-2.66 %)
(As of 11/25/2020 12:00 AM ET)
Today's Range
Now: $1.83
50-Day Range
MA: $2.04
52-Week Range
Now: $1.83
Volume271,977 shs
Average Volume1.42 million shs
Market Capitalization$16.21 million
P/E RatioN/A
Dividend YieldN/A
Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:AKER



Sales & Book Value

Annual Sales$1.58 million
Book Value$2.37 per share


Net Income$-3,890,000.00
Net Margins-489.84%


Market Cap$16.21 million
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable
-0.05 (-2.66 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

How has Akers Biosciences' stock price been impacted by Coronavirus?

Akers Biosciences' stock was trading at $2.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKER stock has decreased by 19.0% and is now trading at $1.83.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Akers Biosciences?

Wall Street analysts have given Akers Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akers Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Akers Biosciences

How were Akers Biosciences' earnings last quarter?

Akers Biosciences, Inc. (NASDAQ:AKER) issued its earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter. The medical instruments supplier earned $0.56 million during the quarter. Akers Biosciences had a negative return on equity of 87.42% and a negative net margin of 489.84%.
View Akers Biosciences' earnings history

Are investors shorting Akers Biosciences?

Akers Biosciences saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 536,600 shares, an increase of 12.2% from the September 30th total of 478,200 shares. Based on an average trading volume of 958,700 shares, the short-interest ratio is presently 0.6 days. Approximately 6.4% of the shares of the stock are sold short.
View Akers Biosciences' Short Interest

Who are some of Akers Biosciences' key competitors?

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioScience (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the following people:
  • Mr. Christopher C. Schreiber, Exec. Chairman, Principal Exec. Officer & Pres (Age 55, Pay $436k)
  • Mr. Stuart Benson, Chief Financial Officer (Age 59)
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 64)

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

Who are Akers Biosciences' major shareholders?

Akers Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include We Are One Seven LLC (0.28%), Wedbush Securities Inc. (0.15%), Private Advisor Group LLC (0.14%) and First Allied Advisory Services Inc. (0.14%).
View institutional ownership trends for Akers Biosciences

Which institutional investors are buying Akers Biosciences stock?

AKER stock was purchased by a variety of institutional investors in the last quarter, including We Are One Seven LLC, Wedbush Securities Inc., Private Advisor Group LLC, and First Allied Advisory Services Inc..
View insider buying and selling activity for Akers Biosciences

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $1.83.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of $16.21 million and generates $1.58 million in revenue each year. Akers Biosciences employs 12 workers across the globe.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is www.akersbio.com.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.